Literature DB >> 3612177

The clinical consequences of X-chromosome inactivation: Duchenne muscular dystrophy in one of monozygotic twins.

S D Pena, G Karpati, S Carpenter, F C Fraser.   

Abstract

We have ascertained retrospectively a female patient, one of identical twins, who was diagnosed at age 23 years as having Duchenne muscular dystrophy (DMD). A muscle biopsy at that time showed a pattern in which large areas of destroyed muscle fibers replaced with adipose tissue were interspersed with normal-appearing muscle fascicles. The visualization of Barr bodies in the muscle biopsy, plus the patient's normal menstrual history served to rule out Turner's syndrome. The clinical expression of DMD in only one of monozygotic twins is strongly suggestive of uneven lyonization, with an excess of paternally derived X-chromosomes being inactivated in the patient. This view is supported by the appearance of the muscle biopsy. Twinning may conceivably predispose to uneven lyonization by reducing the size of the muscle cell anlage at the time of X-chromosome inactivation. Alternatively, lyonization may occur before the splitting of the embryonic mass, and by chance, the two embryonic centers could end up with a significantly different proportion of active maternal and paternal X-chromosomes.

Entities:  

Mesh:

Year:  1987        PMID: 3612177     DOI: 10.1016/0022-510x(87)90240-1

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  9 in total

1.  Different patterns of X inactivation in MZ twins discordant for red-green color-vision deficiency.

Authors:  A L Jørgensen; J Philip; W H Raskind; M Matsushita; B Christensen; V Dreyer; A G Motulsky
Journal:  Am J Hum Genet       Date:  1992-08       Impact factor: 11.025

2.  Uses and limitations of twin studies.

Authors:  S Bundey
Journal:  J Neurol       Date:  1991-10       Impact factor: 4.849

3.  Skewed inactivation of an X chromosome deleted at the dystrophin gene in an asymptomatic mother and her affected daughter.

Authors:  F Tihy; N Vogt; D Recan; B Malfoy; F Leturcq; M Coquet; F Serville; D Fontan; J M Guillard; J C Kaplan
Journal:  Hum Genet       Date:  1994-05       Impact factor: 4.132

4.  X inactivation patterns in female monozygotic twins and their families.

Authors:  E Watkiss; T Webb; G Rysiecki; N Girdler; E Hewett; S Bundey
Journal:  J Med Genet       Date:  1994-10       Impact factor: 6.318

5.  1992 American Society of Human Genetics presidential address: back to the future.

Authors:  W E Nance
Journal:  Am J Hum Genet       Date:  1993-07       Impact factor: 11.025

6.  Skewed X inactivation in a female MZ twin results in Duchenne muscular dystrophy.

Authors:  C S Richards; S C Watkins; E P Hoffman; N R Schneider; I W Milsark; K S Katz; J D Cook; L M Kunkel; J M Cortada
Journal:  Am J Hum Genet       Date:  1990-04       Impact factor: 11.025

7.  Dystrophin insufficiency causes selective muscle histopathology and loss of dystrophin-glycoprotein complex assembly in pig skeletal muscle.

Authors:  Katrin Hollinger; Cai X Yang; Robyn E Montz; Dan Nonneman; Jason W Ross; Joshua T Selsby
Journal:  FASEB J       Date:  2013-12-17       Impact factor: 5.191

8.  Dystrophin analysis in clonal myoblasts derived from a Duchenne muscular dystrophy carrier.

Authors:  O Hurko; E P Hoffman; L McKee; D R Johns; L M Kunkel
Journal:  Am J Hum Genet       Date:  1989-06       Impact factor: 11.025

9.  Genetic characterization in symptomatic female DMD carriers: lack of relationship between X-inactivation, transcriptional DMD allele balancing and phenotype.

Authors:  Simona Brioschi; Francesca Gualandi; Chiara Scotton; Annarita Armaroli; Matteo Bovolenta; Maria S Falzarano; Patrizia Sabatelli; Rita Selvatici; Adele D'Amico; Marika Pane; Giulia Ricci; Gabriele Siciliano; Silvana Tedeschi; Antonella Pini; Liliana Vercelli; Domenico De Grandis; Eugenio Mercuri; Enrico Bertini; Luciano Merlini; Tiziana Mongini; Alessandra Ferlini
Journal:  BMC Med Genet       Date:  2012-08-16       Impact factor: 2.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.